Financials & Filings Supernus Pharmaceuticals. Actinium Pharmaceuticals Home Facebook.
Pharmaceuticals ActiniumвЂ™s Next Generation Lymphodepletion for CAR-T Latest pipeline initiative is a universal tool addressing the unmet needs of the CAR-T space not addressed by current lymphodepletion regimens в™¦Identified new technology opportunity в™¦Idea conceptualized and evaluated в™¦Addresses CAR-T limitations в™¦Expands CAR-T access в™¦Improves CAR-T outcomes Actinium is вЂ¦ Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers provided investors with an update on its business progress following the filing of its 2015 10-K.
Cash Flow Statement (Annual) ATNM / Actinium Pharmaceuticals, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities. detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the вЂњSECвЂќ),including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to
Actinium Pharmaceuticals Inc (ATNM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile SummaryActinium Pharmaceuticals Inc (ATNM), formerly Cactus Ventures, Inc. вЂ¦ Actinium Pharmaceuticals Inc. is focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T with its proprietary, chemotherapy free or sparing, targeted conditioning technology.
CHAIRMANвЂ™S LETTER Novartis Annual Report 2016 3 and immuno-oncology. Partnerships are also vital for our activities in digital health, where we are working to improve evidence-based information about our products and to continue exploring pay-for-performance pricing models. Improving access to healthcare in developing coun-tries is a priority for us, and we are playing our part in helping On September 13, 2017 Actinium Pharmaceuticals, Inc (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, reported that the Company will feature two posters highlighting its Actimab-A Phase 2 and Actimab-M Phase 1 clinical trials
3/01/2019В В· NEW YORK, Jan. 3, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that Sandesh Seth, Actinium's Chairman and Chief Executive Officer will present at the Biotech Showcaseв„ў 2019 being held on January 7-9.. 4/01/2019В В· Actinium Pharmaceuticals, Inc.вЂ™s insider ownership stands at 0.2 percent, while its insider transaction is 0 percent. Institutional Ownership and Transactions Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension вЂ¦:
- Actinium Pharmaceuticals Inc. (ATNM) Earnings Conference
- Actinium Pharmaceuticals Inc. (NYSEATNM) вЂ“ Active Stock
Actinium Pharmaceuticals Inc. Announces 2013 Annual
– ATNM / Actinium Pharmaceuticals, Inc. CURRENT REPORT (Current Report) 2017-12-21 sec.gov UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2017 ACTINIUM PHARMACEUTICALS, INC.. Actinium Pharmaceuticals, Inc. Annual Report 2017. Directors, Offi cers and Corporate Data Directors Sandesh Seth Chairman and CEO David Nicholson* Ajit Shetty** Richard Steinhart** Stockholders and other interested parties may also request information (including copies of the companyвЂ™s п¬Ѓlings with the Securities and Exchange Commission) by contacting Mr. Steve OвЂ™ вЂ¦.
– Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference Nov 19 2018 Actinium Pharmaceuticals to Present at BIO-EuropeВ® 24th Annual International Partnering Conference Nov 05 2018. Email Sign Up. Receive the latest news, events and updates! Sign Up Now. Submit an inquiry through the 'Request Details' form above to request best pricing on this report. Actinium Pharmaceuticals, Inc. (ATNM) is a biopharmaceutical company that develops drugs for the treatment of cancer.. different types of yogurt pdf